These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 34992111)

  • 21. Tenofovir Alafenamide for HIV Prevention: Review of the Proceedings from the Gates Foundation Long-Acting TAF Product Development Meeting.
    Romano JW; Baum MM; Demkovich ZR; Diana F; Dobard C; Feldman PL; Garcia-Lerma JG; Grattoni A; Gunawardana M; Ho DK; Hope TJ; Massud I; Milad M; Moss JA; Pons-Faudoa FP; Roller S; van der Straten A; Srinivasan S; Veazey RS; Zane D
    AIDS Res Hum Retroviruses; 2021 Jun; 37(6):409-420. PubMed ID: 33913760
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial.
    Venter WDF; Sokhela S; Simmons B; Moorhouse M; Fairlie L; Mashabane N; Serenata C; Akpomiemie G; Masenya M; Qavi A; Chandiwana N; McCann K; Norris S; Chersich M; Maartens G; Lalla-Edward S; Vos A; Clayden P; Abrams E; Arulappan N; Hill A
    Lancet HIV; 2020 Oct; 7(10):e666-e676. PubMed ID: 33010240
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial.
    Wohl DA; Yazdanpanah Y; Baumgarten A; Clarke A; Thompson MA; Brinson C; Hagins D; Ramgopal MN; Antinori A; Wei X; Acosta R; Collins SE; Brainard D; Martin H
    Lancet HIV; 2019 Jun; 6(6):e355-e363. PubMed ID: 31068270
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Predicting Pharmacokinetics of a Tenofovir Alafenamide Subcutaneous Implant Using Physiologically Based Pharmacokinetic Modelling.
    Rajoli RKR; Demkovich ZR; Flexner C; Owen A; Siccardi M
    Antimicrob Agents Chemother; 2020 Jul; 64(8):. PubMed ID: 32423957
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.
    Molina JM; Ward D; Brar I; Mills A; Stellbrink HJ; López-Cortés L; Ruane P; Podzamczer D; Brinson C; Custodio J; Liu H; Andreatta K; Martin H; Cheng A; Quirk E
    Lancet HIV; 2018 Jul; 5(7):e357-e365. PubMed ID: 29925489
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Subcutaneous Implant of Tenofovir Alafenamide Fumarate Causes Local Inflammation and Tissue Necrosis in Rabbits and Macaques.
    Su JT; Simpson SM; Sung S; Tfaily EB; Veazey R; Marzinke M; Qiu J; Watrous D; Widanapathirana L; Pearson E; Peet MM; Karunakaran D; Grasperge B; Dobek G; Cain CM; Hope T; Kiser PF
    Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31871073
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Assessing the implementation effectiveness and safety of 1% tenofovir gel provision through family planning services in KwaZulu-Natal, South Africa: study protocol for an open-label randomized controlled trial.
    Mansoor LE; Abdool Karim Q; Mngadi KT; Dlamini S; Montague C; Nkomonde N; Mvandaba N; Baxter C; Gengiah TN; Samsunder N; Dawood H; Grobler A; Frohlich JA; Abdool Karim SS
    Trials; 2014 Dec; 15():496. PubMed ID: 25527071
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial.
    Gallant J; Lazzarin A; Mills A; Orkin C; Podzamczer D; Tebas P; Girard PM; Brar I; Daar ES; Wohl D; Rockstroh J; Wei X; Custodio J; White K; Martin H; Cheng A; Quirk E
    Lancet; 2017 Nov; 390(10107):2063-2072. PubMed ID: 28867497
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Review of the Efficacy and Safety of Genvoya® (Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide) in the Management of HIV-1 Infection.
    Angione SA; Cherian SM; Özdener AE
    J Pharm Pract; 2018 Apr; 31(2):216-221. PubMed ID: 28558493
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study.
    Mills A; Arribas JR; Andrade-Villanueva J; DiPerri G; Van Lunzen J; Koenig E; Elion R; Cavassini M; Madruga JV; Brunetta J; Shamblaw D; DeJesus E; Orkin C; Wohl DA; Brar I; Stephens JL; Girard PM; Huhn G; Plummer A; Liu YP; Cheng AK; McCallister S;
    Lancet Infect Dis; 2016 Jan; 16(1):43-52. PubMed ID: 26538525
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rilpivirine, emtricitabine and tenofovir alafenamide: single-tablet combination for the treatment of HIV-1 infection in selected patients.
    Ogbuagu O
    Expert Rev Anti Infect Ther; 2016 Dec; 14(12):1113-1126. PubMed ID: 27797606
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tenofovir alafenamide use in pregnant and lactating women living with HIV.
    Eke AC; Brooks KM; Gebreyohannes RD; Sheffield JS; Dooley KE; Mirochnick M
    Expert Opin Drug Metab Toxicol; 2020 Apr; 16(4):333-342. PubMed ID: 32125906
    [No Abstract]   [Full Text] [Related]  

  • 33. Safety and pharmacokinetics of single, dual, and triple antiretroviral drug formulations delivered by pod-intravaginal rings designed for HIV-1 prevention: A Phase I trial.
    Vincent KL; Moss JA; Marzinke MA; Hendrix CW; Anton PA; Pyles RB; Guthrie KM; Dawson L; Olive TJ; Butkyavichene I; Churchman SA; Cortez JM; Fanter R; Gunawardana M; Miller CS; Yang F; Rosen RK; Vargas SE; Baum MM
    PLoS Med; 2018 Sep; 15(9):e1002655. PubMed ID: 30265679
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Multispecies Evaluation of a Long-Acting Tenofovir Alafenamide Subdermal Implant for HIV Prophylaxis.
    Gunawardana M; Remedios-Chan M; Sanchez D; Webster S; Galvan P; Fanter R; Castonguay AE; Webster P; Moss JA; Kuo J; Gallay PA; Vincent KL; Motamedi M; Weinberger D; Marzinke MA; Hendrix CW; Baum MM
    Front Pharmacol; 2020; 11():569373. PubMed ID: 33536904
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nanoencapsulation introduces long-acting phenomenon to tenofovir alafenamide and emtricitabine drug combination: A comparative pre-exposure prophylaxis efficacy study against HIV-1 vaginal transmission.
    Mandal S; Kang G; Prathipati PK; Zhou Y; Fan W; Li Q; Destache CJ
    J Control Release; 2019 Jan; 294():216-225. PubMed ID: 30576746
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety and efficacy of a biodegradable implant releasing tenofovir alafenamide for vaginal protection in a macaque model.
    Massud I; Krovi A; Nishiura K; Ruone S; Li L; Holder A; Gary J; Mills P; Mitchell J; Khalil G; Pan Y; Luecke E; Gatto G; Heneine W; García-Lerma JG; Johnson L; van der Straten A; Dobard C
    J Antimicrob Chemother; 2022 Oct; 77(11):2964-2971. PubMed ID: 35913838
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Influences of geo-spatial location on pre-exposure prophylaxis use in South Africa: positioning microbicides for better product uptake.
    Govender EM; Mansoor LE; Abdool Karim Q
    AIDS Care; 2017 Jun; 29(6):734-740. PubMed ID: 27799005
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Why Are Patients Switching from Tenofovir Disoproxil Fumarate/Emtricitabine (Truvada) to Tenofovir Alafenamide/Emtricitabine (Descovy) for Pre-Exposure Prophylaxis?
    D'Angelo AB; Westmoreland DA; Carneiro PB; Johnson J; Grov C
    AIDS Patient Care STDS; 2021 Aug; 35(8):327-334. PubMed ID: 34375141
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Superior Efficacy and Improved Renal and Bone Safety After Switching from a Tenofovir Disoproxil Fumarate- to a Tenofovir Alafenamide-Based Regimen Through 96 Weeks of Treatment.
    DeJesus E; Haas B; Segal-Maurer S; Ramgopal MN; Mills A; Margot N; Liu YP; Makadzange T; McCallister S
    AIDS Res Hum Retroviruses; 2018 Apr; 34(4):337-342. PubMed ID: 29368537
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate in the First Protease Inhibitor-Based Single-Tablet Regimen for Initial HIV-1 Therapy: A Randomized Phase 2 Study.
    Mills A; Crofoot G; McDonald C; Shalit P; Flamm JA; Gathe J; Scribner A; Shamblaw D; Saag M; Cao H; Martin H; Das M; Thomas A; Liu HC; Yan M; Callebaut C; Custodio J; Cheng A; McCallister S
    J Acquir Immune Defic Syndr; 2015 Aug; 69(4):439-45. PubMed ID: 25867913
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.